92469-35-7

Usage

Uses

Used in Pharmaceutical Research and Drug Discovery:
3-(4-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine is utilized as a potential candidate in the development of new medications due to its unique chemical structure and properties. Its presence in pharmaceutical research is attributed to its capacity to be modified and optimized for specific therapeutic targets, thereby contributing to the advancement of novel treatment options.
Used in Organic Synthesis:
In the field of organic synthesis, 3-(4-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine is employed as a building block for constructing more complex molecules. Its versatile structure allows for various chemical reactions, facilitating the creation of a wide array of compounds with diverse applications in different industries.
Used in Chemical Research:
3-(4-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine is also used in chemical research to explore its reactivity, stability, and potential interactions with other molecules. This research aids in understanding the fundamental properties of the compound and can lead to the discovery of new applications and uses in various scientific fields.
Used in Industrial Applications:
3-(4-Methoxyphenyl)-1-methyl-1H-pyrazol-5-amine's unique characteristics make it suitable for various industrial applications, where it may be employed as an intermediate in the synthesis of other chemicals or as a component in the production of specific materials. Its versatility and potential for modification contribute to its value in these applications.

InChI:InChI=1/C11H13N3O/c1-14-11(12)7-10(13-14)8-3-5-9(15-2)6-4-8/h3-7H,12H2,1-2H3

Upstream product

• 57466-68-9 3-chloro-3-(4-methoxyphenyl)acrylonitrile 
• 60-34-4 methylhydrazine 
• 3672-47-7 3-oxo-3-(4'-methoxyphenyl)propanenitrile 
• 100-06-1 1-(4-methoxyphenyl)ethanone 

Downstream Products

• 1415484-55-7 C₂₆H₃₀N₆O₂ 
• 126418-07-3 N-[5-(4-Methoxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-4-methyl-benzenesulfonamide 

Relevant academic research and scientific papers

HSP90 INHIBITORS AND USES THEREOF

Herein is described the design and synthesis of resorcylate aminopyrazole compounds. These compounds show broad, potent and fungal-selective Hsp90 inhibitory activity. These compounds also find use in treating Hsp90 related deseases.

Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors

The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone is also critically important, however, to the pathogen's hu

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors

In anaplastic large-cell lymphomas, chromosomal translocations involving the kinase domain of anaplastic lymphoma kinase (ALK), generally fused to the 5' part of the nucleophosmin gene, produce highly oncogenic ALK fusion proteins that deregulate cell cycle, apoptosis, and differentiation in these cells. Other fusion oncoproteins involving ALK, such as echinoderm microtubule-associated protein-like 4-ALK, were recently found in patients with non-small-cell lung, breast, and colorectal cancers. Recent research has focused on the development of inhibitors for targeted therapy of these ALK-positive tumors. Because kinase inhibitors that target the inactive conformation are thought to be more specific than ATP-targeted inhibitors, we investigated the possibility of using two known inhibitors, doramapimod and sorafenib, which target inactive kinases, to design new urea derivatives as ALK inhibitors. We generated a homology model of ALK in its inactive conformation complexed with doramapimod or sorafenib in its active site. The results elucidated why doramapimod is a weak inhibitor and why sorafenib does not inhibit ALK. Virtual screening of commercially available compounds using the homology model of ALK yielded candidate inhibitors, which were tested using biochemical assays. Herein we present the design, synthesis, biological activity, and structure-activity relationships of a novel series of urea compounds as potent ALK inhibitors. Some compounds showed inhibition of purified ALK in the high nanomolar range and selective antiproliferative activity on ALK-positive cells.